|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0502 SEK | -10.68% |
|
+14.09% | -47.16% |
Prostatype Genomics AB (publ) reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported sales was SEK 0.304313 million compared to SEK 0.735019 million a year ago. Revenue was SEK 0.304313 million compared to SEK 0.735019 million a year ago.
Net loss was SEK 8.16 million compared to SEK 5.75 million a year ago. Basic loss per share from continuing operations was SEK 0.36.
| 1st Jan change | Capi. | |
|---|---|---|
| -47.16% | 5.21M | |
| -22.04% | 8.54B | |
| +68.22% | 4.32B | |
| -0.82% | 2.53B | |
| -9.46% | 2.46B | |
| -38.23% | 2.48B | |
| -7.85% | 1.9B | |
| -17.74% | 1.59B | |
| -39.48% | 1.23B | |
| +9.68% | 1.13B |
PROSTATYPE GENOMICS AB 